VLA1553

BIOLOGICAL6 trials

Sponsors

Valneva Austria GmbH, VALNEVA AUSTRIA GMBH

Conditions

ChikungunyaChikungunya Virus Infection

Phase 1

Study to Assess the Safety and Immunogenicity of a Chikungunya Virus Vaccine Candidate (VLA1553) in Healthy Volunteers

CompletedNCT03382964

Valneva Austria GmbHChikungunya

Start: 2018-03-05End: 2019-07-28Updated: 2019-08-29

Phase 3

Pivotal Study to Evaluate Safety and Immunogenicity of a Live-Attenuated Chikungunya Virus Vaccine Candidate in Adults

CompletedNCT04546724

Valneva Austria GmbHChikungunya Virus Infection

Start: 2020-09-17End: 2021-10-15Updated: 2023-06-28

Antibody Persistence And Long Term Safety Of A Chikungunya Virus Vaccine (VLA1553)

Active, not recruitingNCT04838444

Valneva Austria GmbHChikungunya Virus Infection

Start: 2021-04-02End: 2031-05-01Updated: 2026-07-09

A Clinical Phase 3 Trial of VLA1553 in Adult Participants with Human Immunodeficiency Virus (HIV)

WithdrawnNCT06028841

Valneva Austria GmbHChikungunya Virus Infection

Start: 2024-04-10End: 2024-08-27Updated: 2024-12-02

A Trial to Evaluate the Safety and Immunogenicity of VLA1553 in Healthy Children

WithdrawnNCT07133178

Valneva Austria GmbHChikungunya Virus Infection

Start: 2026-02-06End: 2027-11-30Updated: 2025-12-31

A Pragmatic Randomized Controlled Trial to Evaluate the Effectiveness and Safety of VLA1553 Against Chikungunya Virus Disease

Active, not recruitingPACTR202508701657421

VALNEVA AUSTRIA GMBHChikungunya Virus Infection

Start: 2025-09-14Target: 20000Updated: 2026-08-03

Related Papers

Cross-neutralizing activity of the chikungunya vaccine VLA1553 against three prevalent chikungunya lineages

Emerging Microbes & Infections2025-02-255 citations

Antibody persistence and safety of a live-attenuated chikungunya virus vaccine up to 2 years after single-dose administration in adults in the USA: a single-arm, multicentre, phase 3b study.

2024-08-1218 citations

Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial.

2023-06-12113 citations

Single-shot live-attenuated chikungunya vaccine in healthy adults: a phase 1, randomised controlled trial.

2020-06-0180 citations